SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 02 Dec, 2017  

sandeep-gokhruTHMB.jpg Only few manufacturers maintaining quality in generic drugs: CEO, Luckys Pharma

sandeep-gokhru.jpg
   Top Stories
» 49% Indian startups now from tier 2, 3 cities: Jitendra Singh
» 'India ranks 3rd in global startup ecosystem & number of unicorns'
» Tripura exported over 9K tonnes of pineapples in 2 years
» CPI inflation eases to 6.71% in July, IIP falls to 12.3%
» Rupee depreciates 12 paise to close at 79.64 against US dollar
SME Times News Bureau | 01 Dec, 2017
In India, there are only few manufacturers those are maintaining high quality in generic drug segment, CEO of Luckys Pharma, Sandeep Gokhru told SME Times in an interview.

India don't have drug regulatory mechanism yet. Media said that the issue of branded drugs versus generic drugs raised among pharma professionals after Prime Minister Narendra Modi talked about bringing a law to ensure that doctors must prescribe only generic names of drugs so that patients can access cheaper versions of branded drugs.
Excerpts of the interview...

Please tell something about your company - Luckys Pharma.

Sandeep Gokhru: We Luckys Pharma in Pharma business since 2001. We started to take franchise from other companies for Indore dist. and gradually increase the business. From 2007 we started our own branding and gradually expanding our business area.

What the present shape and size of your group?
Sandeep Gokhru: Now more than 65 products in our product kitty and we have 106 Franchisee distributors in 16 states and union territories in India.

How you see the prospects in dry powder inhaler market globally?
Sandeep Gokhru: Dry powder inhaler, Inhaler, Nasal Spray, Respule, Critical Care products are our USP and key products. In franchise segment we only company that have all of these range in single platform. You know very well that in this world pollution is increasing day by day and this scenario we have to plan awareness for asthma and regularly updated treatments for a better respiratory system in human body.

What are the major issues this is dealing now a days?

Sandeep Gokhru: Major issue is that now a days Government and so many social groups promoting generics. But in India there are only few Manufacturers those are maintaining best quality in generic segment.

If any person have some problem than that patient will go to doctor to solve that problem than doctor prescribe medicine and he/she have to purchase and cure, that should be the procedure. But we are giving a good amount to doctor for fees and at the time of buying medicine we take substitute like generics or any sub stranded medicine for saving the money and there are no results and patients problem is maintained.

What government can do to overcome those challenges?
Sandeep Gokhru: If Government make any policy for medicine business they have to take advice from some people those are big and medium players in this business.

What are your future plans?

Sandeep Gokhru: After above unique products we are coming with some new unique products and divisions in 2018.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

GENERIC MEDICINES
VIJAY AGRAWAL | Sat Dec 2 10:49:30 2017
Mr. Sandeep Gokhru CEO of LUCKYS PHARMA truely said that there are few co's who are manufacturing quality GENERIC MEDICINES . I'm suffering from multiple problems n I can very well understand n value GENERIC MEDICINES .On reading the above I can appreciate Luckys Pharma's progress & Mr.Sandeep Gokhru's hard work n devotion for giving us quality products. Thanks


 
  Customs Exchange Rates
Currency Import Export
US Dollar
66.20
64.50
UK Pound
87.50
84.65
Euro
78.25
75.65
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
PM Modi's recent US visit to redefine India-US bilateral relations
 Yes
 No
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter